Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid 3-year extension study in postmenopausal osteoporosis
2005-000668-17Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postmenopausal osteoporosis and osteoporosis comparing Zoledronic acid for 6 years total with Zoledronic acid for 3 years then placebo for 3 years (2 arms). Started May 2005; status: completed.
02
Drugs
zoledronic acid
03
Conditions
postmenopausal osteoporosisosteoporosis
Beyond the preview
Go deeper on 2005-000668-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000668-17.